NeurAxis, a medical technology company with an FDA-approved therapy to treat abdominal pain associated with IBS in adolescents aged 11 to 18 years old, tweaked the terms of its initial public offering on Friday. In a filing with the Securities and Exchange Commission, the company said it now plans to offer 1.7 million shares priced at $6 each, while selling shareholders will offer 2.8 million shares.
7 million shares priced at $6 each, while selling shareholders will offer 2.8 million shares. The company previously planned to offer 937,500 shares priced at $8, with selling shareholders to offer 1.8 million shares. The company has applied to list on the New York Stock Exchange under the ticker ‘NRXS.’ Alexander Capital L.P. is sole underwriter on the deal.
Italia Ultime Notizie, Italia Notizie
Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.
Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surgeThe results come amid investor anxiety over the thousands of lawsuits claiming that J&J's talc-based baby powder and other products caused cancer.
Leggi di più »